Published in Semin Oncol on August 01, 2012
Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology (2013) 2.21
Cancer stem cells in the development of liver cancer. J Clin Invest (2013) 2.06
G-CSF Promotes Neuroblastoma Tumorigenicity and Metastasis via STAT3-Dependent Cancer Stem Cell Activation. Cancer Res (2015) 1.74
G-CSF receptor positive neuroblastoma subpopulations are enriched in chemotherapy-resistant or relapsed tumors and are highly tumorigenic. Cancer Res (2013) 1.41
STAT3 Target Genes Relevant to Human Cancers. Cancers (Basel) (2014) 1.29
Inhibition of VEGF expression through blockade of Hif1α and STAT3 signalling mediates the anti-angiogenic effect of melatonin in HepG2 liver cancer cells. Br J Cancer (2013) 1.07
Targeting the Wnt/β-catenin signaling pathway in liver cancer stem cells and hepatocellular carcinoma cell lines with FH535. PLoS One (2014) 1.06
Metformin, a diabetes drug, eliminates tumor-initiating hepatocellular carcinoma cells. PLoS One (2013) 1.06
C8orf4 negatively regulates self-renewal of liver cancer stem cells via suppression of NOTCH2 signalling. Nat Commun (2015) 0.97
Molecular mechanisms of fibrosis-associated promotion of liver carcinogenesis. Toxicol Sci (2013) 0.91
The Multifaceted Roles of STAT3 Signaling in the Progression of Prostate Cancer. Cancers (Basel) (2014) 0.91
The role of the dysfunctional akt-related pathway in cancer: establishment and maintenance of a malignant cell phenotype, resistance to therapy, and future strategies for drug development. Scientifica (Cairo) (2013) 0.89
Integrative genomics identifies YY1AP1 as an oncogenic driver in EpCAM(+) AFP(+) hepatocellular carcinoma. Oncogene (2015) 0.88
Targeting Wnt/β-catenin pathway in hepatocellular carcinoma treatment. World J Gastroenterol (2016) 0.88
β-Catenin knockdown in liver tumor cells by a cell permeable gamma guanidine-based peptide nucleic acid. Curr Cancer Drug Targets (2013) 0.87
Disulfiram eradicates tumor-initiating hepatocellular carcinoma cells in ROS-p38 MAPK pathway-dependent and -independent manners. PLoS One (2014) 0.86
PKI-587 and sorafenib alone and in combination on inhibition of liver cancer stem cell proliferation. J Surg Res (2013) 0.86
CD44 gene polymorphisms on hepatocellular carcinoma susceptibility and clinicopathologic features. Biomed Res Int (2014) 0.86
Research progress and prospects of markers for liver cancer stem cells. World J Gastroenterol (2015) 0.86
Common stemness regulators of embryonic and cancer stem cells. World J Stem Cells (2015) 0.84
Identification of microRNAs specific for epithelial cell adhesion molecule-positive tumor cells in hepatocellular carcinoma. Hepatology (2015) 0.84
Therapeutics targeting CD90-integrin-AMPK-CD133 signal axis in liver cancer. Oncotarget (2015) 0.84
Noninvasive Diagnosis of Hepatocellular Carcinoma: Elaboration on Korean Liver Cancer Study Group-National Cancer Center Korea Practice Guidelines Compared with Other Guidelines and Remaining Issues. Korean J Radiol (2016) 0.83
Nestin overexpression in hepatocellular carcinoma associates with epithelial-mesenchymal transition and chemoresistance. J Exp Clin Cancer Res (2016) 0.83
ZIC2-dependent OCT4 activation drives self-renewal of human liver cancer stem cells. J Clin Invest (2015) 0.83
Dynamic imbalance between cancer cell subpopulations induced by transforming growth factor beta (TGF-β) is associated with a DNA methylome switch. BMC Genomics (2014) 0.82
HCMV activates the IL-6-JAK-STAT3 axis in HepG2 cells and primary human hepatocytes. PLoS One (2013) 0.82
Role for putative hepatocellular carcinoma stem cell subpopulations in biological response to incomplete thermal ablation: in vitro and in vivo pilot study. Cardiovasc Intervent Radiol (2014) 0.81
The Notch pathway promotes the cancer stem cell characteristics of CD90+ cells in hepatocellular carcinoma. Oncotarget (2016) 0.81
Generation of subcutaneous and intrahepatic human hepatocellular carcinoma xenografts in immunodeficient mice. J Vis Exp (2013) 0.80
Stem-like plasticity and heterogeneity of circulating tumor cells: current status and prospect challenges in liver cancer. Oncotarget (2016) 0.80
Role of liver stem cells in hepatocarcinogenesis. World J Stem Cells (2014) 0.79
Cancer stem cells in primary liver cancers: pathological concepts and imaging findings. Korean J Radiol (2015) 0.79
Management of hepatocellular carcinoma: Predictive value of immunohistochemical markers for postoperative survival. World J Hepatol (2015) 0.79
The neuroleptic drug pimozide inhibits stem-like cell maintenance and tumorigenicity in hepatocellular carcinoma. Oncotarget (2017) 0.77
Expression of cancer stem cell biomarkers as a tool for a correct therapeutic approach to hepatocellular carcinoma. Oncoscience (2015) 0.77
Fusion with stem cell makes the hepatocellular carcinoma cells similar to liver tumor-initiating cells. BMC Cancer (2016) 0.76
Matrix stiffness-mediated effects on stemness characteristics occurring in HCC cells. Oncotarget (2016) 0.76
Involvement of inflammation and its related microRNAs in hepatocellular carcinoma. Oncotarget (2016) 0.75
Evidence of Hepatitis B Virus Infection in Cancer and Noncancer Stem Cells Associated with Human Hepatocellular Carcinoma. Can J Infect Dis Med Microbiol (2016) 0.75
MIF/CD74 axis is a target for novel therapies in colon carcinomatosis. J Exp Clin Cancer Res (2017) 0.75
A long term, non-tumorigenic rat hepatocyte cell line and its malignant counterpart, as tools to study hepatocarcinogenesis. Oncotarget (2017) 0.75
GP73-regulated oncolytic adenoviruses possess potent killing effect on human liver cancer stem-like cells. Oncotarget (2016) 0.75
Induction of artificial cancer stem cells from tongue cancer cells by defined reprogramming factors. BMC Cancer (2016) 0.75
Inhibition of STAT3 with the generation 2.5 antisense oligonucleotide, AZD9150, decreases neuroblastoma tumorigenicity and increases chemosensitivity. Clin Cancer Res (2016) 0.75
Sulforaphane improves chemotherapy efficacy by targeting cancer stem cell-like properties via the miR-124/IL-6R/STAT3 axis. Sci Rep (2016) 0.75
Combination of macrophage inflammatory protein 1 alpha with existing therapies to enhance the antitumor effects on murine hepatoma. J Radiat Res (2014) 0.75
The Progress and Prospects of Putative Biomarkers for Liver Cancer Stem Cells in Hepatocellular Carcinoma. Stem Cells Int (2016) 0.75
Global cancer statistics, 2002. CA Cancer J Clin (2005) 119.22
The hallmarks of cancer. Cell (2000) 113.05
Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A (2003) 59.17
Identification of human brain tumour initiating cells. Nature (2004) 38.87
Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med (1997) 32.63
Wnt/beta-catenin signaling in development and disease. Cell (2006) 30.09
Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology (2007) 26.78
A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature (2006) 24.52
Identification and expansion of human colon-cancer-initiating cells. Nature (2006) 24.44
Cancer genes and the pathways they control. Nat Med (2004) 24.22
ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell (2007) 22.89
A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature (1994) 21.59
Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res (2006) 17.42
Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med (1999) 17.03
Tumour stem cells and drug resistance. Nat Rev Cancer (2005) 15.21
Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med (2008) 13.54
Primary liver cancer: worldwide incidence and trends. Gastroenterology (2004) 11.21
Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer (2006) 8.50
Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet (2002) 7.67
Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology (2004) 6.98
Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell (2008) 6.48
MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med (2009) 6.13
Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology (2007) 5.75
EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology (2008) 5.53
Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology (2006) 5.46
Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med (2003) 5.45
Cancer stem cells: mirage or reality? Nat Med (2009) 5.20
Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology (2006) 4.61
Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology (2008) 4.50
EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res (2008) 4.17
Human hepatic stem cells from fetal and postnatal donors. J Exp Med (2007) 4.15
CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene (2007) 3.96
Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection. Lancet (2003) 3.93
Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells. Hepatology (2009) 3.92
Characterization of a side population of cancer cells from human gastrointestinal system. Stem Cells (2005) 3.66
CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer (2007) 3.65
Isolation and molecular characterization of cancer stem cells in MMTV-Wnt-1 murine breast tumors. Stem Cells (2007) 3.60
CD13 is a therapeutic target in human liver cancer stem cells. J Clin Invest (2010) 3.60
Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem Biophys Res Commun (2006) 3.35
Liver regeneration and repair: hepatocytes, progenitor cells, and stem cells. Hepatology (2004) 3.09
Characterization of cells with a high aldehyde dehydrogenase activity from cord blood and acute myeloid leukemia samples. Stem Cells (2005) 3.00
Progenitor/stem cells give rise to liver cancer due to aberrant TGF-beta and IL-6 signaling. Proc Natl Acad Sci U S A (2008) 2.98
miR-130b Promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1. Cell Stem Cell (2010) 2.87
CD24(+) liver tumor-initiating cells drive self-renewal and tumor initiation through STAT3-mediated NANOG regulation. Cell Stem Cell (2011) 2.83
Aldehyde dehydrogenase discriminates the CD133 liver cancer stem cell populations. Mol Cancer Res (2008) 2.82
Activation of hepatic stem cell marker EpCAM by Wnt-beta-catenin signaling in hepatocellular carcinoma. Cancer Res (2007) 2.63
Cancer stem cells in radiation resistance. Cancer Res (2007) 2.59
Cancer stem/progenitor cells are highly enriched in CD133+CD44+ population in hepatocellular carcinoma. Int J Cancer (2010) 2.54
Isolation of multipotent progenitor cells from human fetal liver capable of differentiating into liver and mesenchymal lineages. Proc Natl Acad Sci U S A (2006) 2.32
The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma. Clin Liver Dis (2001) 2.26
Thy-1 as a regulator of cell-cell and cell-matrix interactions in axon regeneration, apoptosis, adhesion, migration, cancer, and fibrosis. FASEB J (2006) 2.15
The AC133 epitope, but not the CD133 protein, is lost upon cancer stem cell differentiation. Cancer Res (2010) 2.12
Differentiation therapy of hepatocellular carcinoma in mice with recombinant adenovirus carrying hepatocyte nuclear factor-4alpha gene. Hepatology (2008) 2.12
Identification of local and circulating cancer stem cells in human liver cancer. Hepatology (2008) 2.02
Wnt/beta-catenin signaling contributes to activation of normal and tumorigenic liver progenitor cells. Cancer Res (2008) 1.98
Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma. Int J Clin Pract (2008) 1.62
Epigenetic regulation of cancer stem cell marker CD133 by transforming growth factor-beta. Hepatology (2010) 1.60
Occurrence of oval-type cells in hepatitis B virus-associated human hepatocarcinogenesis. Hepatology (1992) 1.58
The polycomb gene product BMI1 contributes to the maintenance of tumor-initiating side population cells in hepatocellular carcinoma. Cancer Res (2008) 1.56
Hypoxia: a link between fibrogenesis, angiogenesis, and carcinogenesis in liver disease. Semin Liver Dis (2010) 1.49
Cancer-associated molecular signature in the tissue samples of patients with cirrhosis. Hepatology (2004) 1.41
Aminopeptidase N is involved in cell motility and angiogenesis: its clinical significance in human colon cancer. Gastroenterology (2002) 1.39
Molecular pathogenesis of human hepatocellular carcinoma. Toxicology (2002) 1.35
Granulin-epithelin precursor and ATP-dependent binding cassette (ABC)B5 regulate liver cancer cell chemoresistance. Gastroenterology (2010) 1.34
Protein expression of CD44 (standard and variant isoforms) in hepatocellular carcinoma: relationships with tumor grade, clinicopathologic parameters, p53 expression, and patient survival. J Hepatol (2000) 1.33
Identification of side population cells in human hepatocellular carcinoma cell lines with stepwise metastatic potentials. J Cancer Res Clin Oncol (2008) 1.28
CD13/APN regulates endothelial invasion and filopodia formation. Blood (2007) 1.26
New kids on the block: diagnostic and prognostic microRNAs in hepatocellular carcinoma. Cancer Biol Ther (2009) 1.23
CD24 is a novel predictor for poor prognosis of hepatocellular carcinoma after surgery. Clin Cancer Res (2009) 1.22
Analysis of ABCG2 expression and side population identifies intrinsic drug efflux in the HCC cell line MHCC-97L and its modulation by Akt signaling. Carcinogenesis (2008) 1.18
microRNA-150 inhibits human CD133-positive liver cancer stem cells through negative regulation of the transcription factor c-Myb. Int J Oncol (2011) 1.18
An Akt/hypoxia-inducible factor-1alpha/platelet-derived growth factor-BB autocrine loop mediates hypoxia-induced chemoresistance in liver cancer cells and tumorigenic hepatic progenitor cells. Clin Cancer Res (2009) 1.16
EpCAM expression in normal, non-pathological tissues. Front Biosci (2008) 1.16
Wnt/beta-catenin signaling activates microRNA-181 expression in hepatocellular carcinoma. Cell Biosci (2011) 1.16
Lupeol targets liver tumor-initiating cells through phosphatase and tensin homolog modulation. Hepatology (2010) 1.07
Wnt/beta-catenin pathway in hepatocellular carcinoma pathogenesis and liver physiology. Future Oncol (2008) 1.06
Oncostatin m renders epithelial cell adhesion molecule-positive liver cancer stem cells sensitive to 5-Fluorouracil by inducing hepatocytic differentiation. Cancer Res (2010) 1.05
Hepatic progenitor cells in human fetal liver express the oval cell marker Thy-1. Am J Physiol Gastrointest Liver Physiol (2006) 1.04
Hepatic stem-like cells in hepatoblastoma: expression of cytokeratin 7, albumin and oval cell associated antigens detected by OV-1 and OV-6. Histopathology (1997) 1.02
Histological and culture studies with respect to ABCG2 expression support the existence of a cancer cell hierarchy in human hepatocellular carcinoma. Am J Pathol (2007) 1.02
CD133-positive hepatocellular carcinoma in an area endemic for hepatitis B virus infection. BMC Cancer (2009) 1.02
Cytoplasmic expression of CD133 is an important risk factor for overall survival in hepatocellular carcinoma. Oncol Rep (2010) 0.99
CD44 and VEGF expression in extrahepatic metastasis of human hepatocellular carcinoma. Hepatogastroenterology (2004) 0.95
Overexpression of Thy1/CD90 in human hepatocellular carcinoma is associated with HBV infection and poor prognosis. Acta Histochem (2011) 0.93
Arsenic trioxide plus cisplatin/interferon α-2b/doxorubicin/capecitabine combination chemotherapy for unresectable hepatocellular carcinoma. Hematol Oncol Stem Cell Ther (2011) 0.87
Clinicopathological analysis of CD133 and NCAM human hepatic stem/progenitor cells in damaged livers and hepatocellular carcinomas. Hepatol Res (2009) 0.86
Characterization of CD133+ parenchymal cells in the liver: histology and culture. World J Gastroenterol (2009) 0.83
MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med (2009) 6.13
EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology (2008) 5.53
Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med (2003) 5.45
Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell (2008) 5.11
Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology (2008) 4.50
Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell (2006) 4.33
EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res (2008) 4.17
Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells. Hepatology (2009) 3.92
MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival. Clin Cancer Res (2009) 3.03
A cluster of cooperating tumor-suppressor gene candidates in chromosomal deletions. Proc Natl Acad Sci U S A (2012) 2.85
SIRT2 maintains genome integrity and suppresses tumorigenesis through regulating APC/C activity. Cancer Cell (2011) 2.73
Activation of hepatic stem cell marker EpCAM by Wnt-beta-catenin signaling in hepatocellular carcinoma. Cancer Res (2007) 2.63
A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. Cancer Res (2010) 2.59
Sixty-five gene-based risk score classifier predicts overall survival in hepatocellular carcinoma. Hepatology (2012) 2.40
Temporal and spatial control of nucleophosmin by the Ran-Crm1 complex in centrosome duplication. Nat Cell Biol (2005) 2.15
Cancer stem cells in the development of liver cancer. J Clin Invest (2013) 2.06
The role of cytokines in hepatocellular carcinoma. J Leukoc Biol (2006) 1.75
Gene expression profiling reveals potential biomarkers of human hepatocellular carcinoma. Clin Cancer Res (2007) 1.73
Discrete nature of EpCAM+ and CD90+ cancer stem cells in human hepatocellular carcinoma. Hepatology (2013) 1.73
Integrative genomic identification of genes on 8p associated with hepatocellular carcinoma progression and patient survival. Gastroenterology (2011) 1.68
Sal-like protein 4 (SALL4), a stem cell biomarker in liver cancers. Hepatology (2013) 1.63
Transcriptomic profiling reveals hepatic stem-like gene signatures and interplay of miR-200c and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma. Hepatology (2012) 1.57
Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma. Proc Natl Acad Sci U S A (2013) 1.51
Cancer-associated molecular signature in the tissue samples of patients with cirrhosis. Hepatology (2004) 1.41
Let-7g targets collagen type I alpha2 and inhibits cell migration in hepatocellular carcinoma. J Hepatol (2010) 1.41
Novel therapeutic strategies for targeting liver cancer stem cells. Int J Biol Sci (2011) 1.39
Nucleophosmin and human cancer. Cancer Detect Prev (2006) 1.29
Association of TP53 mutations with stem cell-like gene expression and survival of patients with hepatocellular carcinoma. Gastroenterology (2010) 1.28
Integrated metabolite and gene expression profiles identify lipid biomarkers associated with progression of hepatocellular carcinoma and patient outcomes. Gastroenterology (2013) 1.27
New kids on the block: diagnostic and prognostic microRNAs in hepatocellular carcinoma. Cancer Biol Ther (2009) 1.23
The processing of Holliday junctions by BLM and WRN helicases is regulated by p53. J Biol Chem (2002) 1.22
Gene expression profiling of preneoplastic liver disease and liver cancer: a new era for improved early detection and treatment of these deadly diseases? Carcinogenesis (2003) 1.13
Evaluation of midkine as a diagnostic serum biomarker in hepatocellular carcinoma. Clin Cancer Res (2013) 1.09
Molecular carcinogenesis of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: one step closer to personalized medicine? Cell Biosci (2011) 1.08
Mesothelin as a potential therapeutic target in human cholangiocarcinoma. J Cancer (2010) 1.05
A Yin-Yang balancing act of the lin28/let-7 link in tumorigenesis. J Hepatol (2010) 1.03
SAGE transcript profiles of normal primary human hepatocytes expressing oncogenic hepatitis B virus X protein. FASEB J (2002) 1.01
Cooperation of tumor-derived HBx mutants and p53-249(ser) mutant in regulating cell proliferation, anchorage-independent growth and aneuploidy in a telomerase-immortalized normal human hepatocyte-derived cell line. Int J Cancer (2010) 1.00
Inflammatory and microRNA gene expression as prognostic classifier of Barrett's-associated esophageal adenocarcinoma. Clin Cancer Res (2010) 0.99
microRNA and inflammatory gene expression as prognostic marker for overall survival in esophageal squamous cell carcinoma. Int J Cancer (2012) 0.97
Mechanisms of inactivation of hepatitis a virus by chlorine. Appl Environ Microbiol (2002) 0.92
Modulation of miR-29 expression by α-fetoprotein is linked to the hepatocellular carcinoma epigenome. Hepatology (2014) 0.91
Effect of hepatitis C virus core protein on the molecular profiling of human B lymphocytes. Mol Med (2006) 0.90
Regulatory MiR-148a-ACVR1/BMP circuit defines a cancer stem cell-like aggressive subtype of hepatocellular carcinoma. Hepatology (2015) 0.89
Future of molecular profiling of human hepatocellular carcinoma. Future Oncol (2007) 0.89
Translating the metastasis paradigm from scientific theory to clinical oncology. Clin Cancer Res (2009) 0.89
Mechanisms of inactivation of hepatitis A virus in water by chlorine dioxide. Water Res (2004) 0.88
Human CCR4+ CCR6+ Th17 cells suppress autologous CD8+ T cell responses. J Immunol (2012) 0.87
microRNA Regulation and Its Consequences in Cancer. Curr Pathobiol Rep (2012) 0.82
Power play: scoring our goals for liver cancer with better GWAS study design. J Hepatol (2010) 0.82
Identification of cancer stem cell-related microRNAs in hepatocellular carcinoma. Methods Mol Biol (2012) 0.80
Transforming the microenvironment: a trick of the metastatic cancer cell. Cancer Cell (2012) 0.78
Development of a miR-26 companion diagnostic test for adjuvant interferon-alpha therapy in hepatocellular carcinoma. Int J Biol Sci (2013) 0.78
iSubgraph: integrative genomics for subgroup discovery in hepatocellular carcinoma using graph mining and mixture models. PLoS One (2013) 0.78
At the cancer steering wheel: defining key genomic drivers of liver cancer with next generation sequencing. J Hepatol (2012) 0.75
Identification of genomic functional hotspots with copy number alteration in liver cancer. EURASIP J Bioinform Syst Biol (2013) 0.75
A phase II clinical trial with cytotropic heterogeneous molecular lipids (CHML) for patients with hepatic malignancies. Anticancer Res (2007) 0.75